The two drugs had combined brand and generic sales of approximately $893 million, according to data from QunitilesIMS for the 12 months ended July 2017.
Lupin’s generic will be available in 5-, 20- and 40-mg dosage strengths.
The company has named its current global head of drug development and chief medical officer, Dr. Vasant Narasimhan, as CEO, effective Feb. 1, 2018.
A United States appeals court has revived an antitrust lawsuit against four drug makers, alleging that they hamstrung generics for Lipitor and Effexor XR.
Researchers found that women with high cholesterol were 45% less likely to develop breast cancer than those without high cholesterol, suggesting their treatment for high cholesterol may be a factor.
The patents relative to Restasis are listed in the Orange Book and expire on Aug. 27, 2024, Allergan stated.
Cyltezo will be available as 40mg/0.8mL strength pre-filled glass syringes in 2-count cartons.
The product had brand and generic sales of roughly $484.4 million for the 12 months ended June 2017, according to QuintilesIMS data.